Moteur de recherche d’entreprises européennes
Financement de l’UE (14 M €) : Outils numériques intelligents pour le dépistage de la connectivité cérébrale et l’estimation du risque de démence chez les personnes atteintes de troubles cognitifs … Hor22/01/2021 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Outils numériques intelligents pour le dépistage de la connectivité cérébrale et l’estimation du risque de démence chez les personnes atteintes de troubles cognitifs légers.
More than 10 million Europeans show signs of mild cognitive impairment (MCI), a condition intermediate between normal brain ageing and dementia. The evolution of MCI differs from person to person; some remain stable or return to normal, but 50% progress to dementia within five years. Current practice lacks the necessary screening tools to identify those 50% at risk. The patient’s journey typically takes many years of inefficient clinical follow-ups before a conclusive diagnosis is finally reached. AI-Mind will radically shorten this journey to 1 week through a digital solution that is able to provide a fast and accurate (>95%) prediction for the individual dementia risk. Our AI-Mind platform service, can be easily integrated into existing clinical practices and contains 2 new artificial-intelligence-based tools. The AI-Mind Connector identifies dysfunctional brain networks. The AI-Mind Predictor assesses demen-tia risk using data from the Connector, advanced cognitive tests, genetic biomarkers and important textual variables. Our aim is to set up a European clinical network that will upload patient data to the AI-Mind European cloud platform. The consortium comprises excellent researchers in neuroscience and computer science, from 5 clinical cen-tres, who closely collaborate with 3 SMEs contributing unique technologies, an established data govern-ance body, and Alzheimer Europe. Together, they plan to deliver a medical device of class 2b that can reach TRL7 by the end of the project. AI-Mind represents a major step forward in the risk assessment of dementia. Clinicians will promptly advise therapies to delay the onset of disease, and patients will enjoy independent lives for longer. By offering a globally accessible, cheap and precise tool for dementia pre-diction, AI-Mind will improve the health care system and boost innovation by shifting the R&D of phar-maceutical organisations and other companies to preventive diagnostic methods and therapies for dementia.
| AALTO KORKEAKOULUSAATIO sr | 773 438 € |
| ACCELOPMENT SCHWEIZ AG | 851 250 € |
| Alzheimer Europe | 269 375 € |
| Brainsymph AS | 1 045 814 € |
| DNV AS | 438 895 € |
| F. HOFFMANN-LA ROCHE AG | 0,00 € |
| HUS-YHTYMA | 1 131 350 € |
| Irccs SAN Raffaele Roma Srl | 543 438 € |
| Lurtis Rules SL | 994 375 € |
| Neuroconnect Srl | 571 750 € |
| Oslomet - Storbyuniversitetet | 984 050 € |
| Oslo Universitetssykehus HF | 3 025 904 € |
| PRE Diagnostics AS | 0,00 € |
| ROCHE DIAGNOSTICS INTERNATIONAL AG | 0,00 € |
| STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM | 336 163 € |
| STICHTING RADBOUD UNIVERSITEIT | 0,00 € |
| TALLINN UNIVERSITY | 443 125 € |
| Universidad Complutense de Madrid | 1 169 125 € |
| Universidad Politecnica de Madrid | 0,00 € |
| Universita Cattolica Del Sacro Cuore | 944 938 € |
| Universitetet I Oslo | 475 875 € |
https://cordis.europa.eu/project/id/964220
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.
Les visualisations de "AALTO KORKEAKOULUSAATIO sr - Financement de l’UE (14 M €) : Outils numériques intelligents pour le dépistage de la connectivité cérébrale et l’estimation du risque de démence chez les personnes atteintes de troubles cognitifs …"
sont mis à disposition par
North Data
et peuvent être réutilisées selon les termes de la licence
Creative Commons CC-BY.
